Pharmacy Times

DEC 2015

Pharmacy Times offers relevant, clinical information for pharmacists that they can use in their daily practice. These include OTC and Rx product news, disease conditions, patient education guides, drug diversion and abuse, and more.

Issue link: http://pharmacytimes.epubxp.com/i/614520

Contents of this Issue

Navigation

Page 7 of 70

NEWS & TRENDS PHARMACY DEAN INDICTED ON SEXUAL ASSAULT CHARGES T he dean of the University of Arizona College of Pharmacy has been indicted on felony sexual assault charges following accusations that he attacked a woman at his house. The woman told investigators that she had drinks with a friend in early October and dean Jessie Lyle Bootman, a business acquaintance of hers, had approached them. Bootman allegedly bought the woman and her friend a drink, and then invited the woman to see his house since she worked in real estate. At the house, Bootman purportedly gave her another drink, and a tour. The last thing the woman remembered was trying to get her purse to leave, blacking out, and then waking up the next morning with blood on her hand and face, she told investigators. Detectives searched Bootman's house for evidence of sexual assault and date rape drugs and found incriminating evidence but did not specify what it was. The woman told law enforcement that she did not have a prior sexual relationship with Bootman and did not give consent. The University of Arizona put the pharmacy dean on paid administrative leave from his posi- tion as dean, for which he is paid $287,000 a year. He pleaded not guilty to charges of sexual assault, sexual abuse, and aggravated assault. WALGREENS REACHES DEAL TO ACQUIRE RITE AID W algreens will acquire Rite Aid in a $17.2 billion take- over deal that will combine the nation's second- and third-largest pharmacy chains, pending regulatory approval. Rite Aid currently operates about 4600 drugstores in 31 states. The company has worked to expand its RediClinics and built a portfolio of more than 1800 wellness stores that feature consultation rooms for dis- cussions with pharmacists. Walgreens currently operates more than 13,200 stores across 11 countries, as well as approximately 400 Healthcare Clinics throughout the United States. Rite Aid CEO John Standley stated that the deal "will enhance our store base and expand opportunities as part of the first global pharmacy- led, health and well-being enter- prise." Both companies' boards have approved the transaction, and the deal is expected to close in the sec- ond half of 2016. National Community Pharmacists Association CEO B. Douglas Hoey, RPh, called on regulators to "closely scrutinize" the deal to determine the impact that it may have on small pharmacy owners and the patients they serve. "While large chain pharmacies continue to merge to increase their negotiating leverage, independent community pharmacies continue to fill gaps in patient care in rural, urban, and underserved communities," he said. According to research firm IBISWorld, Rite Aid controls 10% market share of the pharmacy busi- ness, while Walgreens control 51%. 16 PharmacyTimes.com December 2015 FIRST PRADAXA REVERSAL AGENT RECEIVES FDA APPROVAL T he FDA granted acceler- ated approval to Boehringer Ingelheim's idarucizumab (Praxbind) for the rapid reversal of the manufacturer's anticoagulant dabigatran (Pradaxa). Praxbind is the first reversal agent approved specifically for Pradaxa, which ini- tially nabbed the FDA's nod in 2010 for the prevention of stroke and systemic blood clots in patients with atrial fibrillation, as well as for the treatment and prevention of deep venous thrombosis and pulmonary embolism. "The anticoagulant effects of Pradaxa are important and life- saving for some patients, but there are situations where reversal of the drug's effects is medically necessary," stated Richard Pazdur, MD, director of the FDA's Office of Hematology and Oncology Products. "[This] approval offers the medical community an impor- tant tool for managing patients taking Pradaxa in emergency or life-threatening situations when bleeding can't be controlled." Praxbind's labeling recommends that patients resume their antico - agulant therapy as soon as medi- cally appropriate, as reversing the effect of Pradaxa exposes patients to the risk of blood clots and stroke from their initial condition. n For an additional figure, go to PharmacyTimes.com/ publications/issue. MORE @ PHARMACY TIMES.COM What will happen to Rite Aid pharmacists after the Walgreens acquisition? Tweet your thoughts @ Pharmacy_Times]

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmacy Times - DEC 2015